Zhejiang Huahai Pharmaceutical Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Bao Hua Chen
Chief executive officer
CN¥2.2m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 24.8% |
| Management average tenure | 3yrs |
| Board average tenure | 3yrs |
Recent management updates
Recent updates
Cautious Investors Not Rewarding Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Performance Completely
Feb 20
Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Somewhat Strained Balance Sheet
Jan 27Investors Holding Back On Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521)
Oct 22Here's Why Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Meaningful Debt Burden
Sep 25Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 20Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt
May 28There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings
May 06Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel
Mar 22CEO
Bao Hua Chen (62 yo)
no data
Tenure
CN¥2,180,000
Compensation
Mr. Bao Hua Chen serves as the President of TCM BU at Shanghai Pharmaceutical (Group) Co., Ltd. Mr. Chen serves as General Manager, President and Director at Zhejiang Huahai Pharmaceutical Co., Ltd. Mr. Ch...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM, President & Director | no data | CN¥2.18m | 24.75% CN¥ 5.3b | |
| Senior VP & CFO | 3yrs | CN¥1.50m | 0.048% CN¥ 10.3m | |
| VP, Secretary of the Board & Director | no data | CN¥2.01m | 0.10% CN¥ 21.7m | |
| Executive VP & Director | no data | CN¥2.18m | 0.0080% CN¥ 1.7m | |
| Vice President | 3yrs | CN¥1.94m | 0.0082% CN¥ 1.8m | |
| Vice President | 3yrs | CN¥4.97m | 0.0016% CN¥ 343.8k | |
| Vice President | 3yrs | CN¥2.04m | 0.0070% CN¥ 1.5m | |
| Vice President | 3yrs | CN¥2.31m | 0.0070% CN¥ 1.5m | |
| Vice President | 3yrs | CN¥2.17m | 0.067% CN¥ 14.2m | |
| Vice President | no data | CN¥1.78m | 0.0012% CN¥ 258.4k | |
| Vice President | 3yrs | CN¥1.94m | 0.0070% CN¥ 1.5m | |
| Vice President | 3yrs | CN¥2.40m | 0.0040% CN¥ 860.6k |
3.0yrs
Average Tenure
49.5yo
Average Age
Experienced Management: 600521's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM, President & Director | no data | CN¥2.18m | 24.75% CN¥ 5.3b | |
| VP, Secretary of the Board & Director | 8yrs | CN¥2.01m | 0.10% CN¥ 21.7m | |
| Executive VP & Director | 3yrs | CN¥2.18m | 0.0080% CN¥ 1.7m | |
| Director | 3yrs | no data | 0.055% CN¥ 11.7m | |
| Director | 3yrs | no data | 0.00083% CN¥ 177.2k | |
| Chairman of the Supervisory Board | 3yrs | no data | no data | |
| Independent Director | 3yrs | CN¥120.00k | no data | |
| Supervisor | 3yrs | no data | no data | |
| Chairman of the Board | 3yrs | CN¥3.37m | 0.010% CN¥ 2.2m | |
| Employee Representative Supervisor | 3yrs | no data | 0.00027% CN¥ 57.7k | |
| Independent Director | 2.5yrs | no data | no data | |
| Independent Director | 3yrs | no data | no data |
3.0yrs
Average Tenure
61.5yo
Average Age
Experienced Board: 600521's board of directors are considered experienced (3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 09:43 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zhejiang Huahai Pharmaceutical Co., Ltd. is covered by 21 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wanhua Wu | China International Capital Corporation Limited |
| Shanshan Li | China Merchants Securities Co. Ltd. |
| Ling Bo Tu | China Minzu Securities |